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Case Presentation

An 82 year-old Caucasian woman was admitted to the hospital
with marked splenomegaly and pancytopenia. Her primary
care physician noted splenomegaly on physical exam during
a recent visit, and a CT scan of the abdomen was performed
as an outpatient which revealed a massively enlarged spleen.
The patient admitted to losing up to 40 pounds over the past
six months due to decreased appetite and early satiety. She
also reported dyspepsia and a feeling of fullness in her belly
for several months. The patient denied nausea, vomiting,
constipation, or diarrhea. Other symptoms included increased
fatigue, chronically swollen legs, and frequent night sweats two
to three nights per week with occasional fevers. The patient
denied shortness of breath, cough, or chest pain. She complained
of urinary urgency and frequency.
The patient had a past medical history of hypertension and
osteoarthritis in her knees and ankles. Her past surgical history
included cataract surgery and cholecystectomy. Family history
was significant for her mother’s “heart problems” and her father
dying from pneumonia. The patient had never smoked, although
she frequently experienced second hand smoke. She did not
drink, nor did she have a history of alcohol abuse. She never
used any illegal drugs or recreational substances. Medications
on admission included Clonidine 0.1 mg BID and hydrocholorothiazide 12.5 mg every day. She had no known drug allergies.
On physical exam her temperature was 97.8° Fahrenheit, pulse
was 98 beats/minute, and respiration rate was 19 breaths/
minute. Her blood pressure was 129/71 mm Hg, and her oxygen
saturation was 98% while breathing ambient air. The patient was
in no apparent distress and was alert and oriented to time, place,
and self. She was slender with a protuberant abdomen. The
spleen was palpable beyond the umbilicus into the right upper
quadrant. She had no lymphadenopathy. She was pale, but not
jaundiced, and had no apparent ascites. She had a 2/6 systolic
ejection murmur with no heave and a normal PMI. Her lungs
were clear to auscultation bilaterally. She had numbness in her
index and ring finger on both hands and some left-sided facial
numbness in the distribution of the V2 branch of cranial nerve
five. Neurologic exam revealed no other abnormalities. She had
no joint swelling or erythema, but her legs had pitting edema
bilaterally.
On admission, chest radiograph and CT of the abdomen with
contrast showed massive splenomegaly (24.5 X 15.1 X 11.7 cm,
see Figure 1). Her CBC revealed pancytopenia with a white blood
cell count of 2.4 B/L, red blood cells 3.36 B/L, platelets 94 B/L,
hemoglobin 10.6 g/dL, and hematocrit 32.8%. Reticulocyte count
was elevated at 2.1%. Of note, she had an elevated lymphocyte
count of 45.5; neutrophils were low at 36.4. Electrolytes were
within normal limits. Albumin was low at 2.9 g/dL and LDH
was normal at 199 U/L. Her blood smear showed pancytopenia

consistent with her complete blood count along with poikilocytosis and suspected villous lymphocytes. Vitamin B12 was
very low at 52 pmol/L. A Monospot test was non-reactive.
A bone marrow biopsy was performed a few days after
admission along with flow cytometry. The bone marrow biopsy
indicated patches of hypercellularity with lymphoid aggregates
consisting of monotonous, small round cells without cytoplasm
suggestive of small lymphocytes. Paratrabecular aggregates
also were appreciated. The bone marrow had maintained good
hematopoietic activity. Of note, reticulin staining of the bone
marrow was increased in the aggregates indicating that this bone
marrow was more difficult to aspirate and thus aggregate cells
may have been less represented on smear. Markers were used to
stain the bone marrow. A marker for CD3 was used to stain T
cells, which were sprinkled throughout the bone marrow with
a few in the lymphoid aggregates. A marker for CD20 was used
to stain B cells, which were scattered throughout the marrow.
Lymphoid aggregates were predominantly CD20 positive,
suggestive of a B cell lymphoproliferative disorder.

Flow cytometry was used to distinguish what type of
lymphoproliferative disorder was present in this woman’s
bone marrow. Total lymphocytes were 35%, which is
slightly elevated. Of the lymphocytes, 31% were B cells
(15% to 20% is normal). The B cells present were CD10
negative, which eliminated follicular cell lymphoma from
the differential. The B cells were CD5 negative, making
Mantle cell lymphoma and chronic lymphocytic leukemia
(CLL) less likely. There were some B cells that were CD11c
positive, a marker for Hairy cell leukemia; but a more
specific marker for Hairy cell is CD103, which was negative
in this patient’s bone marrow biopsy. Most revealing was
the kappa and lambda Ig marker staining, which is used to
evaluate for clonality. The flow cytometry showed kappa
restricted B cell clonality (see Figure 2). Through a process
of elimination via this analysis, a diagnosis of splenic
marginal zone lymphoma (SMZL) was suspected. There
are no distinguishing markers for SMZL, and this type of
lymphoma shares many markers with other lymphoproliferative diseases. It is interesting to note that there is CD15
positivity in the B cells present in this patient, and perhaps
this marker should be followed in future diagnoses of SMZL
to discover a new correlation.
Discussion

Splenic marginal zone lymphoma (SMZL) is an indolent B-cell
malignancy involving the spleen, bone marrow, and blood. It
is a rare lymphoma type, first described in 1992, and has been
estimated as less than 2% of all patients with lymphoma.2
Splenic marginal zone lymphoma is a disease of the elderly with
a median age at presentation of 65 years old.2 Almost all patients
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present with moderate to massive splenomegaly, sometimes
with abdominal discomfort. Hepatomegaly can sometimes be
observed, but lymphadenopathy is uncommon. Anemia and
thrombocytopenia are common at presentation secondary
to hypersplenism more than bone marrow infiltration.
Autoimmune phenomena, such as primary biliary cirrhosis,
rheumatoid arthritis, immune thrombocytopenia, are present
in 10% to 20% of patients.2,4 Splenic marginal zone lymphoma
is considered a low-grade lymphoma with an indolent clinical
course, and median survival is close to ten years, with five-year
survival estimated to be greater than 65%.1 Approximately 10%
of patients undergo transformation to a high-grade lymphoma.
The diagnosis is based on lymphocyte morphology, immunophenotype, bone marrow histology, cytogenetic abnormalities,
and when available, spleen histology. Approximately 75% of
patients with splenic marginal zone lymphoma will have a
peripheral blood lymphocytosis.2 One of the most characteristic
findings is the presence of villous lymphocytes on peripheral
blood smear, which are intermediate-sized lymphocytes with
condensed chromatin and short cytoplasmic projections.2
However, the amount of circulating cells may be so small, that
it cannot be detected. Infiltration of the bone marrow is evident
in virtually all patients with SMZL, but is invariably involved.
It may be demonstrable only by flow cytometry and not by
morphology alone. The immunophenotype profile for SMZL is
typically positive for CD20, CD45RA, CD45RB, CD79A, PAX5/
BSAP, IgM, and bcl2, and negative for CD43, CD23, CD10,
bc16, and cyclin D1.1
The pattern of bone marrow infiltration can vary and may be
nodular, intransinusoidal, interstitial, and paratrabecular.4
However, intrasinusoidal infiltration is considered to be
characteristic of SMZL. In SMZL, the spleen is enlarged and
splenic sections demonstrate a nodular replacement of white
pulp, usually with a central core of lymphocytes with slightly
irregular nuclei, and an outer zone of larger cells with clear
cytoplasm in the marginal zone. Both cell populations are part
of the neoplastic clone. The splenic red pulp is also involved in
most cases, usually occupying germinal centers and is evident
by immunostaining.5 Although a primary diagnosis of SMZL is
rarely, if ever, made on the basis of lymph node biopsy, splenic
hilar nodes are typically involved. Complex chromosomal
aberrations are common in SMZL; 80% of cases have an
abnormal karyotype, but there is no single abnormality present
in all cases.2 The most frequent cytogenetic aberrations are gains
of 3q and 12q and 7q deletion.2
There is no definitive standard treatment for splenic marginal
zone lymphoma to date. The level of evidence supporting
recommendations for initiating treatment is weak due to the
absence of prospective clinical trials. Currently treatment is
based on clinical evidence obtained from clinical centers with
experience in treating SMZL. Due to the indolent course of
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SMZL, about two thirds of patients are asymptomatic at diagnosis
and as many as one third will never require therapy. In general,
the development of lymphadenopathy, high lymphocyte count,
or infiltration of non-hematopoietic sites have been found to
be associated with progression and shorter overall survival. 2
Progression may also be associated with a transformation to a
high grade lymphoma.
However, therapeutic intervention should be considered in
patients with active disease. Considering the indolent course of
SMZL, the patient’s age and comorbidities, treatment should be
aimed at achieving control of the disease and symptoms rather
than eradication of the disease.2 There are several therapeutic
options effective in these patients including splenectomy,
chemotherapy, and irradiation. Symptomatic splenomegaly
or severe cytopenia are the main indications to perform
splenectomy. However, splenectomy alone cannot reduce the
extrasplenic lymphomatous infiltrations, and one group has
reported an increase of tumor burden in the bone marrow
after splenectomy.1 Splenic irradiation has been used in a
limited number of patients and has been reported to produce
a reduction in circulating villous lymphocytes, regression of
splenomegaly, and improvement of cytopenias.1 Chemotherapy
is generally used as a first line treatment in people with more
advanced disease. Alkylating agents appear to be of marginal
benefit. Purine analogs, such as fludarabine in combination
with rituximab, or rituximab alone, have demonstrated a
greater efficacy than alkylating agents in terms of response and
progression-free survival.2
Our patient’s clinical presentation and findings were consistent with
splenic marginal zone lymphoma. She received splenic irradiation
and underwent splenectomy for symptomatic splenomegaly. She is
currently undergoing chemotherapy with Rituxan.

Figure 1. On CT of the abdomen with contrast, the spleen was
found to be massively enlarged measuring at least 24.5 X 15.1 X
11.7 cm and is homogenously enhancing.
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Figure 2. All three flow cytometry graphs show kappa-restricted B cell clonality, suggestive of a B cell lymphoproliferative disease. Graph A shows
only kappa positive marker; the same cells are negative for lambda marker. CD19 is a marker for B cells, and is utilized in Graph B and C. Graph
B displays CD19 positive cells are also kappa positive, but they are lambda negative (in Graph C).
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